Cat. No.: HY-170621

STAT1/3-IN-1

Customer Review

Based on 1 Customer Validation

STAT1/3-IN-1 is a potent STAT1/3 inhibitor with potent anti-inflammatory effect. STAT1/3-IN-1 inhibits phosphorylation and nuclear translocation of STAT1/3 to modulate microglial inflammation, reduces LPS (HY-D1056)-induced pro-inflammatory cytokines (NO, IL-1β, IL-6, and TNF-α) and inflammatory mediators (iNOS, COX-2). STAT1/3-IN-1 exhibits low toxicity in mice. STAT1/3-IN-1 can be used for the research of neuroinflammation.

For research use only. We do not sell to patients.

Purity: 99.23%
CAS No.: 2958649-56-2
Formula: C₂₈H₂₅ClN₆O₅
Molecular Weight:560.99

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

STAT1/3-IN-1 Chemical Structure

CAS No.: 2958649-56-2

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

COX-2

IL-6

iNOS

STAT3

STAT1

IL-1β

TNF-α

All STAT Isoforms :

All NO Synthase Isoforms :

All COX Isoforms :

All Interleukin Related Isoforms :

All TNF Receptor Isoforms :

In Vitro

STAT1/3-IN-1 (compound 6k) (1-10 μM, 26 h) inhibits LPS-induced NO production with an IC₅₀ of 4.45 μM, while maintains cell viability in BV-2 cells^[1].
STAT1/3-IN-1 (5-10 μM; 8 h) significantly downregulates mRNA expression of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and inflammatory mediators (iNOS, COX-2) in LPS-stimulated BV-2 cells^[1].
STAT1/3-IN-1 (5-10 μM) reduces LPS-induced IL-6 and TNF-α release in BV-2 cells^[1].
STAT1/3-IN-1 (5-10 μM; 26 h) dose-dependently reduces iNOS and COX-2 protein expression in LPS-stimulated BV-2 cells^[1].
STAT1/3-IN-1 (5-10 μM; 5 h) inhibits STAT1 and STAT3 phosphorylation and reduces nuclear phosphorylated STAT1 and STAT3 in LPS-stimulated BV-2 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Real Time qPCR^[1]

Cell Line:

LPS-stimulated BV-2 cells
Concentration:

5, 10 μM
Incubation Time:

8 h (2 h pretreatment + 6 h with LPS)
Result:

Significantly downregulated mRNA expression of IL-1β, IL-6, TNF-α, iNOS and COX-2 in LPS-stimulated BV-2 cells.

Western Blot Analysis^[1]

Cell Line:

LPS-stimulated BV-2 cells
Concentration:

5, 10 μM
Incubation Time:

26 h (2 h pretreatment + 24 h with LPS)
Result:

Decreased LPS-induced iNOS and COX-2 protein expression in a concentration-dependent manner.

Western Blot Analysis^[1]

Cell Line:

LPS-stimulated BV-2 cells
Concentration:

5, 10 μM
Incubation Time:

5 h (2 h pretreatment + 3 h with LPS)
Result:

Abrogated LPS-induced phosphorylation of STAT1 and STAT3.

Immunofluorescence^[1]

Cell Line:

LPS-stimulated BV-2 cells
Concentration:

10 μM
Incubation Time:

5 h (2 h pretreatment + 3 h with LPS)
Result:

Significantly reduced nuclear presence of phosphorylated STAT1 and STAT3 under LPS stimulation.

Western Blot Analysis^[1]

Cell Line:

LPS-stimulated BV-2 cells
Concentration:

10 μM
Incubation Time:

5 h (2 h pretreatment + 3 h with LPS)
Result:

Decreased levels of phosphorylated STAT1 and STAT3 in nuclear extracts under LPS stimulation.

Cell Viability Assay^[1]

Cell Line:

LPS-stimulated BV-2 cells
Concentration:

1, 10 μM
Incubation Time:

26 h (2 h pretreatment + 24 h with LPS)
Result:

Showed no significant cytotoxicity, with cell viability of 88.03% (1 μM) and 86.71% (10 μM) compared to the control group.

In Vivo

STAT1/3-IN-1 (compound 6k) (250 mg/kg; i.g.; single dose) shows low acute toxicity in KM mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male and female KM mice^[1]
Dosage:

250 mg/kg
Administration:

i.g.; single dose
Result:

Showed no significant differences in body weight, organ indices, GPT and GOT levels compared to vehicle control.
Showed no significant damage in major organs (heart, liver, spleen, lungs, and kidneys).

Chemical Information

CAS No. 2958649-56-2
Appearance Solid
Molecular Weight 560.99
Formula C₂₈H₂₅ClN₆O₅
Color White to off-white
SMILES

ClC1=C(N2C=C(C3=CC=CC(NC(C4=CN(C[C@@](OCC[C@H]5C)([H])N5C6=O)C6=C(OC)C4=O)=O)=C3)N=N2)C=CC=C1
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (178.26 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7826 mL

8.9128 mL

17.8256 mL

5 mM

0.3565 mL

1.7826 mL

3.5651 mL

10 mM

0.1783 mL

0.8913 mL

1.7826 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5 mg/mL (8.91 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Hou X, et al. Synthesis of dolutegravir derivatives modified by 1,2,3-triazole structure and their anti-inflammatory activity in LPS-induced BV2 cells. Bioorg Med Chem Lett. 2025;117:130076. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.7826 mL	8.9128 mL	17.8256 mL	44.5641 mL
	5 mM	0.3565 mL	1.7826 mL	3.5651 mL	8.9128 mL
	10 mM	0.1783 mL	0.8913 mL	1.7826 mL	4.4564 mL
	15 mM	0.1188 mL	0.5942 mL	1.1884 mL	2.9709 mL
	20 mM	0.0891 mL	0.4456 mL	0.8913 mL	2.2282 mL
	25 mM	0.0713 mL	0.3565 mL	0.7130 mL	1.7826 mL
	30 mM	0.0594 mL	0.2971 mL	0.5942 mL	1.4855 mL
	40 mM	0.0446 mL	0.2228 mL	0.4456 mL	1.1141 mL
	50 mM	0.0357 mL	0.1783 mL	0.3565 mL	0.8913 mL
	60 mM	0.0297 mL	0.1485 mL	0.2971 mL	0.7427 mL
	80 mM	0.0223 mL	0.1114 mL	0.2228 mL	0.5571 mL
	100 mM	0.0178 mL	0.0891 mL	0.1783 mL	0.4456 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

STAT1/3-IN-1

Apoptosis Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Pyroptosis Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Lactylation Compound Library

All STAT Isoforms

All NO Synthase Isoforms

All COX Isoforms

All Interleukin Related Isoforms

All TNF Receptor Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

STAT1/3-IN-1 Related Classifications

Cat. No.: HY-170621